Monte Rosa Therapeutics (NasdaqGS:GLUE) announced a new supply agreement with Johnson & Johnson to evaluate MRT-2359 with ...
Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 TALAPRO-3 study of TALZENNA® (talazoparib), ...
InvestorsHub on MSN
Pfizer’s TALZENNA combination shows progress against prostate cancer
Pfizer Inc. (NYSE:PFE) announced that its Phase 3 TALAPRO-3 clinical trial met its primary endpoint, demonstrating that the ...
Zacks Investment Research on MSN
PFE Talzenna combo shows strong efficacy in wider prostate cancer use
Pfizer PFE reported positive top-line results from a late-stage study evaluating Talzenna (talazoparib), an oral PARP ...
While sales of Talzenna, which Pfizer acquired in a $14 billion deal, have been “negligible” so far, the new results should ...
Pfizer announces phase 3 TALAPRO-3 study of talzenna plus Xtandi significantly improves rPFS in metastatic prostate cancer: New York Friday, March 20, 2026, 09:00 Hrs [IST] Pfizer ...
Pfizer is eyeing an earlier use of its PARP inhibitor Talzenna after a positive phase 3 trial in metastatic hormone-sensitive ...
Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 TALAPRO-3 study of TALZENNA® (talazoparib), an oral poly ADP-ribose ...
The effects of the extent of lymph node dissection during radical prostatectomy on prostate cancer survival outcomes have been unclear, pending long-term follow-up data from randomized controlled ...
Prostate cancer is one of the leading causes of cancer-related death in men, and some experts project the number of cases to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results